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Vasoactive intestinal peptide 
axis is dysfunctional in patients 
with Graves’ disease
M. carrión1,4, A. M. Ramos‑Leví2,4, I. V. Seoane1, R. Martínez‑Hernández2, 
A. Serrano‑Somavilla2, D. Castro1, Y. Juarranz1, I. González‑Álvaro3, Rosa P. Gomariz1,5* & 
Mónica Marazuela2,5
Vasoactive intestinal peptide (VIP) is a neuropeptide with potent immunoregulatory properties. 
Reduced serum VIP levels and alterations in VIP receptors/signaling on immune cells have been 
associated with different inflammatory/autoimmune diseases. However, its role in autoimmune 
thyroid diseases (AITD) remains unknown. This study examined the interrelationship between VIP 
system, autoimmune background and thyroid hormones in peripheral immune cells in patients with 
AITD. Only Graves’ disease (GD) patients showed significantly lower serum VIP levels when compared 
to healthy subjects and to Hashimoto’s thyroiditis patients. Serum VIP levels were lower at the onset 
of GD, showing a significant negative correlation with thyroid hormone levels. The expression of VIP 
receptors, VPAC1 and VPAC2, was significantly upregulated in peripheral blood mononuclear cells 
(PBMC) from GD patients. There was an impairment of VIP signalling in these patients, probably 
attributable to a dysfunction of VPAC1 with preservation of VPAC2. The correlation between VPAC1 
and thyroid hormone receptor expression in PBMC from healthy subjects was lost in GD patients. 
In summary, the VIP system is altered in peripheral immune cells of GD patients and this finding is 
associated with different thyroid hormone receptor patterns, showing a dynamic inter‑regulation and 
a prominent role of VIP in this setting.
Experimental data and clinical observations in animal models and humans point to an important role of inter-
actions between neuroendocrine and immune systems for the maintenance of the overall  homeostasis1,2. This 
bidirectional network is functionally supported by the presence of shared signalling molecules, including hor-
mones, neuropeptides, cytokines, and their respective receptors. Thus, neuropeptides and hormones are able to 
modulate immune functions, and immune mediators are capable of affecting the endocrine system. Therefore, 
although the immune system itself has mechanisms of self-regulation, the neuroendocrine system is also involved 
in its control. Accordingly, impairment of mechanisms mediating such regulatory relationships has been linked 
with the development of autoimmune  diseases3.
Thyroid hormones, triiodothyronine (T3) and thyroxine (T4), are implicated in key physiological processes, 
including development, differentiation, and regulation of  metabolism4. Besides, accumulating evidence proves 
the impact of thyroid status on immune responses and inflammation, by directly affecting the functional activity 
of monocytes, macrophages, lymphocytes and natural  killer3. Biological actions of thyroid hormones are medi-
ated by classical signalling mechanisms initiated through binding to their corresponding nuclear receptors, TRα 
and TRβ, that directly modulate gene  transcription5. In addition, recent investigations have described that they 
also act at the plasma membrane via integrin αvβ3, triggering signalling cascades that indirectly contribute to 
the regulation of gene  expression4.
Thyroid autoimmune diseases (AITD) include a broad spectrum of disorders, with Graves’ disease (GD) and 
Hashimoto’s thyroiditis (HT) being the most frequently  observed6–8. GD is characterized by the presence of serum 
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autoantibodies directed against the thyrotropin (TSH) receptor (TRAb), which over-activate this receptor in 
thyrocytes, leading to thyroid hormone hyperproduction and unrestrained release. At the time of diagnosis, GD 
patients exhibit serum FT4 levels above the normal reference range and are classified as hyperthyroid patients. 
There are different treatment options available for GD such as antithyroid drugs, radioiodine and surgery (thy-
roidectomy), which may allow some patients to recover the normal FT4 levels, thus being classified as euthyroid 
GD patients. On the other hand, HT represents the archetype for T-cell-mediated degenerative diseases. It is 
characterized by a progressive autoimmune thyrocyte depletion, resulting in impaired thyroid hormone produc-
tion and clinical  hypothyroidism9.
Vasoactive intestinal peptide (VIP) is a homeostatic peptide secreted by nerve endings, endocrine and 
immune cells, with potent immunoregulatory and anti-inflammatory properties. The main signalling pathway 
mediating VIP effects is activation of adenylate cyclase (AC) through its specific Protein G coupled receptors, 
VPAC1 and  VPAC210. The role of VIP in inflammatory disorders has been broadly reported. Specifically, exog-
enous VIP administration exhibits beneficial effects in murine models of inflammatory/autoimmune disorders, 
by reducing immune reactions and inducing anti-inflammatory  mediators11,12. Moreover, in vitro studies on 
human cells have validated the ability of VIP to reshape both innate and adaptive immune responses. VIP impairs 
acquisition of the macrophage proinflammatory polarization  profile13, and alters the Th1/Th2 balance in CD4 T 
cell differentiation in favour of Th2 cells, stimulating the acquisition of a Th17 non-pathogenic profile and induc-
ing regulatory T cells (Treg)14. Furthermore, reduced serum VIP levels have been described in different inflam-
matory/autoimmune diseases, emerging as a potential prognostic biomarker in patients with early  arthritis15,16 
and early spondyloarthritis (SpA)17. In this sense, alterations in the expression and functionality of VIP receptors 
have also been observed in these autoimmune disorders, portraying an association with disease  activity18,19.
Given the relationship between thyroid and immune function, our hypothesis was that both the autoim-
mune process and the alterations of thyroid hormone levels in AITD could be interrelated with changes in the 
VIP system, which, in turn, would modulate the immune response. Therefore, we first explored if serum VIP 
levels were altered in patients with GD or HT, and if these alterations were related to relevant clinical param-
eters or associated with different thyroid status. We then studied the expression and function of VIP receptors 
in peripheral blood mononuclear cells (PBMC). In addition, we characterized the expression pattern of thyroid 
hormone receptors in order to elucidate if alterations in either of these systems in PBMC could be involved in 
thyroid autoimmune diseases.
Results
Serum VIP levels are decreased in hyperthyroid GD patients. Given that a decreased expression of 
VIP has been reported in several autoimmune and inflammatory diseases, we first evaluated serum levels of VIP 
in GD and HT patients, in an attempt to explore its relevance in two clinically opposed thyroid autoimmune 
diseases. We also evaluated thyroid hormone levels and thyroid autoantibodies (Table 1a).
Regarding serum VIP levels, there were no differences between sexes and no significant correlation with 
age were observed. Likewise, no differences were detected between smokers and non-smokers, or in patients 
with or without family past medical history of autoimmune or thyroid disease. Interestingly, only GD patients 
showed significantly lower serum levels of VIP (median normalized: 334.24 pmol/ml) when compared to healthy 
subjects (364.11 pmol/ml) and with HT patients (361.42 pmol/ml) (Fig. 1a). Correlation and regression analysis 
were performed between VIP serum levels and relevant clinical parameters on each group of patients, includ-
ing serum levels of FT4, TSH, TPOAb, TgAb and TRAb, age and sex. These analyses only revealed a significant 
negative correlation between VIP serum levels and FT4 levels in GD patients (B = − 7.709, P = 0.021), but no 
other significant relationships were found (data not shown).
To further examine the altered levels of VIP found in the group of GD patients, VIP serum concentrations 
were analysed in relation to the thyroid hormone status of these patients. VIP levels were only decreased in 
recently diagnosed hyperthyroid GD patients but not in euthyroid or hypothyroid patients after therapy (Table 1b, 
Fig. 1b). Specifically, patients who had not received any prior treatment for hyperthyroidism had the lowest 
median serum VIP levels (325.08 pg/ml) compared to patients who had received anti-thyroid drugs (345.01 pg/
ml, P = 0.006) or radioiodine (361.92 pg/ml, P = 0.024). The number of patients that had undergone previous 
surgery was lower, but we also observed a trend for higher VIP levels (350.65 pg/ml) than treatment-naïve 
patients (P = 0.065). Interestingly, we did not find significant differences in serum VIP levels between the three 
treatment groups (Fig. 1c). Therefore, our results revealed that diminished VIP levels in GD patients are only 
associated with the hyperthyroid status.
Increased expression and altered function of VIP receptors, VPAC1 and VPAC2, in PBMC from 
GD patients. Once confirmed that serum VIP levels were only reduced in hyperthyroid GD patients and 
given that we hypothesized that the alterations of thyroid hormone system might be interrelated with the VIP 
axis, we next examined the expression and functionality of VIP receptors in PBMC from both euthyroid and 
hyperthyroid GD patients.
We found that VPAC1 and VPAC2 transcripts levels were significantly upregulated in GD patients, in both 
hyperthyroid and euthyroid status when compared with healthy donors (Fig. 2a). Gene expression of VPAC1 
was similarly high in both GD groups, whereas increase for VPAC2 mRNA expression was more pronounced 
in patients with normal thyroid status.
We then assessed protein expression of VIP receptors by means of Western blot. Results showed that VPAC1 
and VPAC2 protein levels were significantly higher in PBMC from GD patients compared to healthy donors 
(Fig. 2b), in agreement with mRNA results. We then explored if these changes in receptor expression entailed 
an alteration in their function. As AC signalling pathway is the major transduction route mediating VIP effects, 
3
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13018  | https://doi.org/10.1038/s41598-020-70138-3
www.nature.com/scientificreports/
intracellular cAMP accumulation in PBMC was measured following stimulation with VIP or VPAC selective 
agonists (Table 2). We found that cAMP production elicited by VIP was significantly reduced in PBMC from 
hyperthyroid GD patients compared with healthy donors, whereas PBMC from euthyroid GD patients displayed 
a non-significant decrease in the VIP potency to stimulate AC activity. VPAC1 agonist-induction of intracellular 
cAMP was significantly decreased in all GD patients, being almost abolished in the euthyroid group. Conversely, 
VPAC2 agonist maintained its functional capacity to induce cAMP accumulation and showed an improved abil-
ity in euthyroid patients, reaching levels comparable to those induced by VIP in PBMC from healthy donors. 
Collectively, our findings showed an increased expression of VPAC1 and VPAC2 receptors in PBMC from GD 
patients. Hyperthyroid GD patients exhibited an impairment in VIP signalling not found in the euthyroid group 
which displayed a higher expression and improved functionality of VPAC2 receptors.
Thyroid hormone receptors are increased in PBMC from GD patients and its expression is 
related to the VIP system. Given that PBMC from both hyperthyroid and euthyroid GD patients exhib-
ited a variation in VIP receptors, we next assessed whether thyroid hormone receptors were also altered. To 
that end, we examined the gene expression of the nuclear thyroid hormone receptors TRα and TRβ (THRA 
and THRB, respectively), and the plasma membrane integrin αvβ3 (codified by ITGAV and ITGB3 genes) were 
examined in PBMC from patients with GD and healthy donors. Then, we studied its relationship with the VIP 
axis.
Transcript levels of thyroid hormone receptors, with the exception of THRA, were significantly increased in 
hyperthyroid GD patients compared to healthy donors (Fig. 3a, b).
When we explored the possible relationship between the altered expression patterns of receptors for VIP and 
for thyroid hormone, a significant correlation was found between the gene expression of VPAC1 and all genes 
encoding thyroid hormone receptors in PBMC from healthy donors (Table 3). Specifically, there were positive 
correlations between mRNA expression levels of VPAC1, the nuclear receptors THRA, THRB and the ITGAV 
subunit of integrin, whereas a negative correlation was found with the subunit ITGB3. Conversely, none of these 
correlations were found in hyperthyroid GD patients, whereas euthyroid GD patients retained positive correla-
tions with THRA and ITGAV while recovered the negativity in the correlation with ITGB3 subunit, although 
not statistically significant (Table 3). Regarding VPAC2, only a significant positive correlation for ITGAV was 
found in healthy subjects, which was not observed in GD (Table 3). Hence, our results showed an imbalance in 
the expression pattern of VIP receptors and thyroid hormone receptors in PBMC from GD patients. The rela-
tionship observed between gene expression profiles of both types of receptors in healthy subjects was lost in the 
hyperthyroid group, whereas was partially retained in euthyroid patients.
Table 1.  Demographic and clinical characteristics of AITD patients and healthy donors. (a) Patients with 
different autoimmune thyroid diseases and healthy donors. (b) Subgroups of patients with Graves’ disease. 
Values are given as the median and (interquartile range). HD (healthy donor), HT (Hashimoto’s thyroiditis), 
GD (Graves’ disease), FT4 (free thyroxine 4), TSH (thyroid-stimulating hormone), TPOAb (thyroid peroxidase 
antibody), TgAb (thyroglobulin antibody), TRAb (TSH-receptor antibody), VIP (vasoactive intestinal 
peptide), NA (not available). Normal reference values for hormones and autoantibodies are: FT4 (ng/dl): 
0.93–1.7; TSH (uU/ml): 0.27–5; TPOAb (UI/ml) < 100; TgAb (UI/ml) < 344; TRAb (U/l) < 0.7. P values are 








(n = 144) P value
Age (years) NA 49 (35–55) 49 (37–56) 0.51
Sex (female) NA 63 114 0.777
FT4 (ng/dl) NA 1.17 (0.93–1.40) 1.60 (1.14–2.55) 0.000
TSH (uU/ ml) NA 4.01 (2.09–6.67) 0.01 (0.00–0.98) 0.000
TPOAb(UI/ml) 20 (0–20) 438 (174–771) 155 (20–461) 0.000
TgAb (UI/ml) 20 (0–20) 336 (20–991) 20 (20–557) 0.002
TRAb (U/l) 0 (0–0) 0.47 (0.19–0.69) 2.70 (1.28–7.63) 0.000
VIP (pg/ml) 364.11 (331.11–416.88) 361.42 (309.28–424.03) 334.24 (303.75–373.58) 0.003
b Euthyroid GD (n = 36) Hyperthyroid GD (n = 73) Hypothyroid GD (n = 35) P value
Sex (female) 30 55 29 0.518
Age (years) 48 (40–54) 47 (33–57) 52 (33–60) 0.773
FT4 (ng/dl) 1.12 (0.93–1.27) 2.42 (1.95–3.36) 1.19 (0.72–1.57) 0.000
TSH (uU/ ml) 0.24 (0.01–1.94) 0 (0–0.01) 2.31 (0.5–10.16) 0.000
TPOAb (UI/ml) 155 (20–459) 165 (20–613) 70 (20–300) 0.297
TgAb (UI/ml) 20 (20–319) 20 (20–649) 20 (20–552) 0.156
TRAb (U/ml) 2.39 (1.2–9.89) 2.72 (1.58–8.0) 3.21 (0.83–7.21) 0.015
VIP (pg/ml) 346.07 (318.42–394.23) 325.08 (295.73–351.29) 353.63 (325.79–389.92) 0.000
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Figure 1.  VIP serum levels in patients with different thyroid function status. (a) Association between VIP 
levels and thyroid status. ELISA determinations of VIP serum levels in 78 patients with Hashimoto’s thyroiditis 
(HT), 144 with Graves’ disease (GD), and 49 healthy donors (HD). (b) Association between VIP serum levels 
and thyroid function in patients with GD. ELISA determinations of VIP concentration in serum from 73 GD 
patients at the initial onset of the disease, 36 euthyroid GD patients controlled with antithyroid drugs and 35 GD 
hypothyroid patients due to treatment iatrogenesis. (c) Association between VIP levels and treatment groups in 
patients with GD. ELISA determinations of VIP concentration in serum from 73 GD patients with no treatment, 
36 treated with anti-thyroid drugs, 21 treated with radioiodine and 14 that underwent surgery. Data are 
presented as the interquartile range (p75 upper edge of the box, p25 lower edge, p50 midline), p90 (line above 
the box), and p10 (line below the box) of serum VIP levels. Dots represent outliers. *P < 0.05; **P < 0.01.
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Figure 2.  Characterization of VIP receptors in PBMC from healthy donors and from both hyperthyroid and 
euthyroid GD patients. (a) VPAC1 and VPAC2 mRNA expression levels in PBMC were determined by real-time 
PCR. Results are expressed as relative mRNA expression (relative to GAPDH mRNA levels) and referred to the 
expression level in healthy donors. Determinations were done in triplicate, and means and SEM are shown. (b) 
Protein levels of VPAC1 and VPAC2 in lysates of PBMC were measured by Western blotting. Protein bands were 
analyzed by densitometric analysis and normalized against the intensity of β-actin. Results are the mean ± SEM 
of at least 3 experiments and representative pictures are shown. *P < 0.05; **P < 0.01; ***P < 0.001.
Table 2.  Effect of VIP, VPAC1 agonist, and VPAC2 agonist on intracellular cAMP levels in PBMC. 
Intracellular cAMP levels were determined by ELISA in PBMC unstimulated or stimulated for 60 min with 
VIP (10 nM), VPAC1 agonist (10 nM), or VPAC2 agonist (10 nM). Determinations were done in duplicate. 
Data are expressed as pmol cAMP/mg protein, and means and SEM are shown. P values less than 0.05 were 








Basal 0.38 ± 0.09 0.24 ± 0.05 0.31 ± 0.23
VIP, 10 nM 1.34 ± 0.22 0.42 ± 0.85* 0.51 ± 0.09
VPAC1 agonist, 10 nM 1.76 ± 0.25 0.47 ± 0.05** 0.05 ± 0.04***
VPAC2 agonist, 10 nM 0.97 ± 0.18 0.97 ± 0.23 1.6 ± 0.41
Figure 3.  Gene expression of nuclear thyroid hormone receptors, TRα and TRβ, and plasma membrane 
integrin αvβ3 in PBMC from healthy donors and from both hyperthyroid and euthyroid GD patients. The 
mRNA expression levels of (a) THRA and THRB, and (b) ITGAV and ITGB3 in PBMC were determined by real-
time PCR. Results are expressed as relative mRNA expression (relative to GAPDH mRNA levels) and referred to 
the expression level in healthy donors. Determinations were done in triplicate, and means and SEM are shown. 
*P < 0.05; ***P < 0.001.
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Discussion
A complex network of immune-neuroendocrine regulatory interactions, mediated by hormones, neuropeptides 
and other signalling molecules, is crucial in the maintenance of  homeostasis1. In this regard, potent anti-inflam-
matory and immunomodulatory effects of VIP have been demonstrated in several inflammatory/autoimmune 
diseases, where reduced serum levels of this neuropeptide and alterations in its signalling pathway in immune 
cells have been  described10,11,20. Thyroid hormone levels, on their part, exhibit a positive correlation with markers 
of inflammation and immune activation, and thus, they may exacerbate the alterations of VIP  axis21. However, 
the potential involvement of VIP in the particular case of autoimmune thyroid disease, which represent a model 
of autoimmunity and inflammation with abnormal thyroid hormones  levels22 is not fully understood.
In the present study, we describe that VIP serum levels are significantly reduced in GD patients at the onset of 
the disease, when thyroid hormone levels are elevated (hyperthyroid status). On the contrary, no significant vari-
ations of VIP levels were observed in GD patients with normal thyroid status (euthyroid patients) or iatrogenic 
hypothyroidism. Levels of VIP were normalized in euthyroid GD patients independently of the treatment used 
to control hyperthyroidism, including antithyroid drugs, radioiodine or surgery. Accordingly, we also observed 
a negative correlation between VIP and FT4 serum levels in GD patients, whereas no significant relationships 
were found with other clinical parameters, including TSH, TgAb, TPOAb, and TRAb. It is worthy to note that 
variations in these clinical parameters are considered not specific for GD since can also be found in other AITDs 
and even in healthy subjects. However, thyroid hormone status of GD patients is evaluated on the basis of serum 
FT4 levels. Therefore, hyperthyroid GD patients show FT4 levels above the normal reference range whereas the 
euthyroid group has normal or near-normal hormonal values. In other words, our results convey that patients 
with an ongoing autoimmune thyroid hyperactivity exhibit significantly lower serum levels of VIP, suggesting 
that the increased serum FT4 levels could be a contributing factor to the decreased VIP levels in hyperthyroid GD 
patients. Our hypothesis is in agreement with previous reports in murine models which demonstrated modula-
tory effects of thyroid hormone on VIP mRNA levels in different adult brain  areas23 and an upregulation of VIP 
content in the anterior pituitary gland under hypothyroid  conditions24–26. Besides, our results link GD to other 
inflammatory/autoimmune diseases where VIP serum levels are decreased, such as juvenile idiopathic arthri-
tis (JIA)27, early  arthritis15,  SpA17,  osteoarthritis28 and  asthma29. Moreover, the fact that only the hyperthyroid 
subgroup with recent onset GD showed reduced VIP levels, suggests an association between low VIP levels and 
disease activity, as it has also been previously demonstrated in patients with early  arthritis15,16,  SpA17, Chagas 
 cardiomyopathy30 and  JIA27. In this regard, GD activity has been associated with high levels of pathogenic Th17 
and impaired Treg  response31–33. These data would indeed be in accordance with the low VIP levels found at the 
onset of GD, given that VIP is able to promote Treg responses in several autoimmune  diseases34,35, and induces 
a non-pathogenic phenotype in in vitro differentiated Th17  cells36. Therefore, it is worth speculating that GD 
might represent an additional autoimmune disease in which a disruption of VIP-mediated immune homeostasis 
could be linked to clinical outcome. Nevertheless, longitudinal studies in larger population samples would be 
useful to verify the potential role of VIP as a biomarker of GD activity.
Considering the hypothesis of an alteration of the VIP axis on immune cells, we characterized VIP receptors 
in PBMC from patients with GD and related these findings to thyroid status. Our findings showed an upregula-
tion of VPAC1 and VPAC2 in GD patients as a group, in accordance with the dynamic regulation of both recep-
tors reported in several autoimmune diseases, such as in PBMC and T cells from early arthritis  patients14,18,in 
monocytes from rheumatoid arthritis (RA)  patients37,in  CD4+ T cells from multiple sclerosis (MS)  patients38, and 
in monocytes from Sjögren’s syndrome (SS)  patients39. Despite the higher expression of VPAC receptors, VIP-
stimulated signalling through VPAC1 receptor was significantly impaired in both hyperthyroid and euthyroid 
GD patients, whereas VPAC2 preserved its functional capacity. Interestingly, a remarkable increase in VPAC2 
transcript levels was observed in PBMC from euthyroid GD patients compared to the hyperthyroid group. 
Therefore, the enhanced expression of VPAC2 could be considered as a mechanism that attempts to counterbal-
ance the VPAC1 dysfunction by upregulating the expression of the functional receptor. Furthermore, VPAC2 
agonist also displayed an improved ability to increase intracellular cAMP in euthyroid GD PBMC compared 
with healthy donors, suggesting a reinforcement of VPAC2 mediated signalling. This compensatory mechanism 
through VPAC2 would not be operating in the hyperthyroid group, which exhibited a impairment in VIP signal-
ling. These data are in agreement with the role of VPAC2 in mediating VIP anti-inflammatory effects in synovial 
fibroblasts from RA patients that showed a reduced expression of  VPAC140. Moreover, our results point that, also 
Table 3.  Correlation between gene expression of the receptors for VIP and for thyroid hormone in PBMC. 
Spearman’s correlation test performed with the relative mRNA expression levels of VPAC1 or VPAC2 and 
Thyroid hormone receptors. Spearman’s correlation coefficients (rho) are shown, and statistical signification is 







VPAC1 VPAC2 VPAC1 VPAC2 VPAC1 VPAC2
THRA 0.3609** − 0.0329 0.3059 0.4011* 0.8464*** 0.2714
THRB 0.4597*** 0.4152 0.1068 0.232 − 0.3107 − 0.0964
ITGAV 0.4911*** 0.6923*** 0.1148 0.3553 0.6321* 0.0678
ITGB3 − 0.4638*** − 0.2129 0.2637 0.243 − 0.0514 − 0.1429
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in GD, VPAC2 expression is probably related to cellular activation and/or pathological  conditions19. In this sense, 
VPAC2 also become the dominant receptor in PBMC, activated memory Th cells and Th17-polarized cells from 
early arthritis  patients14,18. Moreover monocytes from SS patients exhibit higher expression of VPAC2, which 
is absent in healthy donors  monocytes39, and activated  CD4+ T cells isolated from patients with MS also show a 
remarkable increase in the expression of  VPAC238.
Regarding thyroid hormone receptors, as far as we know, our results reveal for the first time an altered expres-
sion pattern of these receptors in PBMC from GD patients. Transcript levels of the nuclear TRβ receptor were 
significantly upregulated in all GD patients, whereas plasma membrane receptor αvβ3 was only increased in 
hyperthyroid GD patients. When we examined the interplay between the systems involving VIP and thyroid hor-
mones in healthy subjects, we found a positive correlation between the relative expression of VPAC1 and thyroid 
hormone receptors mRNA, with the exception of the integrin β3 subunit which exhibited a negative correlation. 
Such negative relationship may reflect a limiting interaction between expression of VPAC1 and ITGB3, by which 
the presence of the integrin heterodimer on the plasma membrane might be regulated. Interestingly, all correla-
tions were lost in hyperthyroid GD patients, whereas the euthyroid group recovered the positive correlations 
with THRA and ITGAV genes, and also, the negativity in the correlation with ITGB3, although not statistically 
significant. Therefore, the restoration of such immune-neuroendocrine interactions in patients with normal 
thyroid status after medical treatment could be interpreted as an additional evidence of the direct relationship 
between these  systems1, suggesting the existence of reciprocal regulatory mechanism.
In summary, our findings of reduced serum VIP levels and dysfunctional VPAC signalling in PBMC from 
hyperthyroid GD patients, suggest the existence of a dynamic connection between the neuroendocrine and 
immune systems and a prominent role of VIP in this setting (Fig. 4). Although further studies are needed to 
corroborate this hypothesis, our results represent an initial step to unravel the neuroendocrine-immune regula-
tory interactions in the specific setting of GD, which could certainly open new opportunities for therapeutic 
intervention.
Methods
Study population. We evaluated 222 patients (177 women, 79.7%) with AIDT: 78 with HT and 144 with 
GD. Diagnosis was established on commonly accepted clinical and laboratory  criteria41. Specifically, diagno-
sis of HT was made when TSH levels were above the upper limit of normal (> 5 uU/ml), with or without low 
serum free T4 (FT4), and positive antibodies against thyroperoxidase (TPOAb > 100 U/ml) and/or thyroglobu-
lin (TgAb > 344 U/ml). GD, on its part, was diagnosed when TSH levels were below the lower limit of normal 
(< 0.27 uU/ml), with or without elevated FT4 (> 1.7 ng/dl) and positive TSH Receptor antibodies (TRAb > 1U/
ml). Another 49 healthy subjects, matched for age and sex, were included as controls. Complete clinical and 
Figure 4.  Graphical schematic representation for the proposed inter-relationship between thyroid hormone 
and VIP system in GD patients. VIP serum levels are significantly lower and negatively correlated with FT4 
in hyperthyroid GD patients. Transcript levels of VIP receptors (VPAC1 and VPAC2) and thyroid hormone 
receptors (nuclear TRβ and plasma membrane αvβ3) are increased in GD patients compared to healthy 
donors, with the exception of TRα. GD patients show an impairment of VIP signalling through VPAC1 (dotted 
blue arrows), whereas VPAC2 maintains its capacity to stimulate AC activity (solid blue arrows). There is a 
correlation between the relative expression of VPAC1 and thyroid hormone receptors in healthy donors (solid 
black arrows) which is lost in hyperthyroid GD patients (dotted black arrows), suggesting the existence of 
interactions between both systems in this group of patients. (PBMC peripheral blood mononuclear cell, FT4 free 
thyroxine 4, AC adenylate cyclase. Blue arrows indicate the contribution of each VPAC receptor signalling to AC 
activation. Bi-directional black arrows represent correlation between VPAC1 and thyroid hormone receptors).
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demographic data were collected for all patients, including age, sex, history of tobacco, history of other autoim-
mune diseases, presence of thyroid diseases in other members of the family, goiter, orbital alterations, and previ-
ous therapies (anti-thyroid drugs, radioiodine, surgery or levothyroxine). No patient had been previously treated 
with steroids. 47 patients (21.2%) acknowledged a smoking habit and 60 patients (27.0%) recalled some sort of 
past family medical history regarding thyroid disease.
Clinical status at the time of blood sampling was evaluated in each of the 144 patients with GD and catego-
rized as follows. We considered patients as “hyperthyroid GD, initial onset” when blood was collected at the time 
diagnosis and FT4 levels were above the normal reference limit (1.7 ng/ml); “euthyroid GD”, when patients were 
on anti-thyroid drugs and had normal or near-normal hormonal values; and “hypothyroid GD” for patients who 
developed hypothyroidism as a consequence of overtreatment with antithyroid drugs, or after therapy with radio-
active iodine or surgery if they were not yet adequately replaced with thyroid hormone. Regarding treatments 
received by GD patients: 36 patients (25.0%) had received anti-thyroid drugs, 21 (14.6%) radioiodine and 14 
(9.7%) had undergone surgery. The remaining 73 patients (50.7%) were naïve to any thyroid-directed treatment.
An informed consent was obtained from all patients participating in the study.
All the procedures were reviewed and approved by the Research Ethics Committee of Instituto de Investi-
gación Sanitaria La Princesa (Madrid, Spain), and were in accordance with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. All patients signed an informed consent form before 
sampling.
Clinical, hormonal and autoantibody evaluation. Serum levels of FT4, TSH and TgAb, TPOAb, and 
TRAb were analyzed for each patient. FT4 levels were measured by radioimmunoassay (RIA) with Amerlex FT4 
RIA kit (Trinity Biotech); plasma TSH was determined by a highly sensitive radioimmunometric assay Diagnost 
hTSH (Boehring Co); levels of TRAb were measured by enzyme-linked immunosorbent assay (ELISA) (DRG 
Instruments GmbH); levels of TgAb and TPOAb were assessed by the immunoradiometric assays ImmunoCAP 
Thyroglobulin and Immuno-CAP Thyroid Peroxidase kits (Phadia AB).
evaluation of levels of vasoactive intestinal peptide. We assessed levels of VIP using a commer-
cially available competitive ELISA kit (Phoenix Pharmaceuticals), as previously  described17. Serum samples 
were freeze-dried and dissolved in ELISA buffer (2:1). Levels of VIP were determined applying the correspond-
ing dilution factor. Samples from each patient were assayed twice. The minimum detectable concentration was 
0.12 ng/ml, with an intra-assay and inter-assay variation of ≤ 5 and 15%, respectively.
Human peripheral blood mononuclear cells. PBMC from healthy donors, hyperthyroid GD patients 
and euthyroid GD patients were isolated from heparinized peripheral blood by density gradient centrifugation 
on Ficoll-Hypaque (Sigma Aldrich).
RNA extraction, cDNA synthesis and real‑time polymerase chain reaction (PCR). As previ-
ously described in Carrion et al.13, total RNA was extracted using TriReagent method (Sigma Aldrich). RNA 
quantity and purity were measured on a NanoDrop and 2 µg were used for cDNA synthesis using a High Capac-
ity cDNA Reverse Transcription Kit (Life Technologies). Real-time PCR analysis for all target genes and one 
house keeping gene (GADPH) were performed using TaqMan Gene Expression Master Mix (Life Technologies), 
with manufacturer-predesigned primers. Assays were made in triplicate, and results were normalized according 
to the expression levels of GADPH. Results were obtained using the 2-ΔΔCt method for quantification.
Western blot analysis of VPAC1 and VPAC2 receptors. As previously described in Carrion et al.13 
PBMC proteins were extracted in ice-cold radioimmunoprecipitation assay buffer (50 mM Tris–HCl pH 7.5, 
150 mM NaCl, 30 mM NaF, 5 mM EDTA, 1% Triton X-100, 1% NP-40, 0.1% SDS, 1 mM DTT, 1 mM sodium 
orthovanadate, protease inhibitor cocktail). 30 μg and 40 μg protein extracts, for VPAC1 and VPAC2 respectively, 
were subjected to 10% SDS-PAGE and transferred to PVDF membranes (BioRad). After blocking, membranes 
were incubated overnight at 4ºC with rabbit polyclonal anti-human VPAC1 (1: 15,000; Thermo Scientific) and 
mouse monoclonal anti-human VPAC2 (1: 1000; Abnova Corporation). Mouse anti β-actin (1:20,000, Sigma-
Aldrich), was used as a loading control. Horseradish peroxidase conjugated secondary antibody (1:10,000, Santa 
Cruz Biotechnology) was used. Proteins were detected using Western Blotting Luminol reagent (Santa Cruz 
Biotechnology), analyzed using the Bio-Rad Quantity One program and normalized against β-actin.
Determination of intracellular cAMP concentrations. Levels of cAMP were determined by an ELISA 
kit (ADI-900-066, Enzo Life Sciences). PBMC obtained from 18 healthy subjects, 9 hyperthyroid GD patients 
and 5 euthyroid GD patients were cultured in RPMI-1640-GlutaMAX media (Life Technologies) supplemented 
with 10% FBS (Lonza,) plus 1% penicillin/streptomycin. After cells were treated with 10 nM VIP (Polypeptide 
Group), VPAC1 agonist  [Lys15Arg16Leu27-VIP (1-7)-GRF (8-27)], or VPAC2 agonist (RO 25-1553) (Bachem) 
for 60 min, the reaction was terminated by aspiration of the growth medium and addition of 0.1 N HCl. The 
concentrations of cAMP in the cell lysates were measured according to the manufacturer’s instructions. Protein 
concentration was determined using a QuantiPro BCA Assay Kit (Sigma- Aldrich).
Statistical analysis. Descriptive results are given as mean ± standard deviation and median (interquartile 
range) for normally- and not-normally-distributed continuous variables, respectively. Categorical variables were 
summarized as frequencies and percentages.
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In order to overcome the batch effect, which is intrinsic to ELISA determinations, the results obtained for VIP 
levels were homogenized. Association of VIP levels with patients’ characteristics was assessed using two-sided 
analysis of variance (Kruskal–Wallis or U-Mann Whitney tests, as required), general linear models, logistic and 
linear regression analysis and bivariate correlations (Spearman).
All statistical analyses were performed using SPSS version 21.0 (IBM SPSS Statistics Inc.). The P values 
were two-sided and statistical significance was considered when P < 0.05. Significance of results was analysed 
using the GraphPad Prism software version 6 (Graphpad Software Inc.). Data were subjected to normality test 
(Kolmogórov-Smirnov test) and equal variance test (F-test). Mann Whitney or Kruskal–Wallis test was used 
in intergroup comparison between not-normally-distributed continuous variables. P values less than 0.05 were 
considered significant (*P < 0.05; **P < 0.01; ***P < 0.001). Results are expressed as the mean ± standard error of 
the mean (SEM).
Data availability
All relevant data are within the paper. The datasets generated and/or analysed during the current study are not 
publicly available due to the confidential nature of the clinical data but are available from the corresponding 
author on reasonable request.
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